Evidence map›Paper›PMID 41708113›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Acute Muscle Injury and Subcutaneous Edema in a Patient with Anti-nuclear Matrix Protein-2 Antibody Positive Dermatomyositis Sine Dermatitis.

Emi Minekawa, Yohsuke Oto, Yoshinao Muro, Ichizo Nishino, Takeshi Fukuda, Ken Yoshida, Taro Ukichi

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emi MinekawaDivision of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa Hospital, Japan.
Yohsuke OtoDivision of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa Hospital, Japan.
Yoshinao MuroDepartment of Dermatology, Nagoya University Graduate School of Medicine, Japan.
Ichizo NishinoDepartment of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan.
Takeshi FukudaDepartment of Radiology, The Jikei University School of Medicine, Japan.
Ken YoshidaDivision of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Taro UkichiDivision of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case describes anti-nuclear matrix protein-2 (NXP-2) antibody-positive dermatomyositis sine dermatitis (DMSD) with an acute onset and marked creatine kinase (CK) elevation, closely mimicking drug-induced rhabdomyolysis. The patient lacked a skin rash and initially improved with hydration, but later developed respiratory failure, leading to a diagnosis via a muscle biopsy and antibody testing. Notably, the imaging findings also resembled rhabdomyolysis, further complicating differentiation. This case highlights that when anti-NXP-2-positive myositis presents as DMSD with acute, transient CK elevation and rhabdomyolysis-like imaging, however, distinguishing between these two conditions is extremely difficult. In such atypical cases, a muscle biopsy plays a critical role and should be actively considered for the diagnosis.

Indexed as

AutoantibodiesDermatomyositisEdemaRNA-Binding ProteinsHumansMaleRhabdomyolysisAutoantibodiesRNA-Binding Proteinsanti-nuclear matrix protein-2 antibodydermatomyositisdermatomyositis sine dermatitisrhabdomyolysis

Identifiers

PMID41708113
PMCPMC13668788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.